Anorectic state of obesity medications in the United States. Are leaner times ahead?

Research output: Contribution to journalArticle

Abstract

Introduction: Obesity is considered to be a chronic disease. Currently there are five prescription-only medications on the US market for the long-term management of obesity. However, these medications are underutilized by obese or overweight individuals seeking medical assistance for weight management. Areas covered: This special report provides an overview of the emerging obesity pharmacotherapies based on the data available from recruiting and active phase II/III trials from a registry of clinical trials. The authors also give their expert opinion and provide their future perspectives on the treatment of obesity based on what is known. Expert opinion: Despite obesity being a chronic condition affecting 40% of the US population, there is a low demand for obesity medications in the US market. Although the potential obesity medications that are currently being investigated in phase II/III clinical trials are promising, it is unclear whether the future pharmacotherapies will be enough to meet the health care need.

Original languageEnglish (US)
Pages (from-to)167-172
Number of pages6
JournalExpert Opinion on Pharmacotherapy
Volume21
Issue number2
DOIs
StatePublished - Jan 22 2020

Fingerprint

Appetite Depressants
Obesity
Expert Testimony
Medical Assistance
Drug Therapy
Phase III Clinical Trials
Phase II Clinical Trials
Prescriptions
Registries
Chronic Disease
Clinical Trials
Delivery of Health Care
Weights and Measures
Population

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Keywords

  • MEDI0382
  • Orlistat
  • dapagliflozin
  • liraglutide
  • lorcaserin
  • naltrexone/bupropion
  • phentermine/topiramate
  • semaglutide
  • setmelanotide
  • tesofensine

Cite this

@article{9cc6b5e32bd5467e973c3dc48e8d9b3e,
title = "Anorectic state of obesity medications in the United States. Are leaner times ahead?",
abstract = "Introduction: Obesity is considered to be a chronic disease. Currently there are five prescription-only medications on the US market for the long-term management of obesity. However, these medications are underutilized by obese or overweight individuals seeking medical assistance for weight management. Areas covered: This special report provides an overview of the emerging obesity pharmacotherapies based on the data available from recruiting and active phase II/III trials from a registry of clinical trials. The authors also give their expert opinion and provide their future perspectives on the treatment of obesity based on what is known. Expert opinion: Despite obesity being a chronic condition affecting 40{\%} of the US population, there is a low demand for obesity medications in the US market. Although the potential obesity medications that are currently being investigated in phase II/III clinical trials are promising, it is unclear whether the future pharmacotherapies will be enough to meet the health care need.",
keywords = "MEDI0382, Orlistat, dapagliflozin, liraglutide, lorcaserin, naltrexone/bupropion, phentermine/topiramate, semaglutide, setmelanotide, tesofensine",
author = "Xinyi Li and Bello, {Nicholas T.}",
year = "2020",
month = "1",
day = "22",
doi = "10.1080/14656566.2019.1692815",
language = "English (US)",
volume = "21",
pages = "167--172",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "2",

}

Anorectic state of obesity medications in the United States. Are leaner times ahead? / Li, Xinyi; Bello, Nicholas T.

In: Expert Opinion on Pharmacotherapy, Vol. 21, No. 2, 22.01.2020, p. 167-172.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anorectic state of obesity medications in the United States. Are leaner times ahead?

AU - Li, Xinyi

AU - Bello, Nicholas T.

PY - 2020/1/22

Y1 - 2020/1/22

N2 - Introduction: Obesity is considered to be a chronic disease. Currently there are five prescription-only medications on the US market for the long-term management of obesity. However, these medications are underutilized by obese or overweight individuals seeking medical assistance for weight management. Areas covered: This special report provides an overview of the emerging obesity pharmacotherapies based on the data available from recruiting and active phase II/III trials from a registry of clinical trials. The authors also give their expert opinion and provide their future perspectives on the treatment of obesity based on what is known. Expert opinion: Despite obesity being a chronic condition affecting 40% of the US population, there is a low demand for obesity medications in the US market. Although the potential obesity medications that are currently being investigated in phase II/III clinical trials are promising, it is unclear whether the future pharmacotherapies will be enough to meet the health care need.

AB - Introduction: Obesity is considered to be a chronic disease. Currently there are five prescription-only medications on the US market for the long-term management of obesity. However, these medications are underutilized by obese or overweight individuals seeking medical assistance for weight management. Areas covered: This special report provides an overview of the emerging obesity pharmacotherapies based on the data available from recruiting and active phase II/III trials from a registry of clinical trials. The authors also give their expert opinion and provide their future perspectives on the treatment of obesity based on what is known. Expert opinion: Despite obesity being a chronic condition affecting 40% of the US population, there is a low demand for obesity medications in the US market. Although the potential obesity medications that are currently being investigated in phase II/III clinical trials are promising, it is unclear whether the future pharmacotherapies will be enough to meet the health care need.

KW - MEDI0382

KW - Orlistat

KW - dapagliflozin

KW - liraglutide

KW - lorcaserin

KW - naltrexone/bupropion

KW - phentermine/topiramate

KW - semaglutide

KW - setmelanotide

KW - tesofensine

UR - http://www.scopus.com/inward/record.url?scp=85075472689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075472689&partnerID=8YFLogxK

U2 - 10.1080/14656566.2019.1692815

DO - 10.1080/14656566.2019.1692815

M3 - Article

AN - SCOPUS:85075472689

VL - 21

SP - 167

EP - 172

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 2

ER -